Study of a Respiratory Syncytial Virus/human Metapneumovirus/Parainfluenza Virus type 3 Vaccine Candidate in Adults Aged 60 Years and Older

Trial Identifier: VBD00006
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: September 2024
Primary Completion Date: March 2026
Study Completion Date: March 2026
Condition: Parainfluenza Immunisation; Respiratory Syncytial Virus Immunisation; Metapneumovirus immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia, New South Wales Blacktown, New South Wales, Australia, 2148
Australia, New South Wales Kanwal, New South Wales, Australia, 2259
Australia, Queensland Herston, Queensland, Australia, 4006
Australia, Victoria Camberwell, Victoria, Australia, 3124
AUSTRALIA, New South Wales Botany, New South Wales, AUSTRALIA, 2019
AUSTRALIA, New South Wales Brookvale, New South Wales, AUSTRALIA, 2100
AUSTRALIA, New South Wales MIRANDA, New South Wales, AUSTRALIA, 2228
AUSTRALIA, Victoria Bayswater, Victoria, AUSTRALIA, 3153